Continued use of zonisamide following development of renal calculi.
Richards
Karen C
KC
Peter Kellaway Section of Neurophysiology, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.
Smith
Michael C
MC
Verma
Amit
A
D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use*; D019355:Calcium Citrate / Q000627:therapeutic use; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005440:Fluid Therapy; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D007669:Kidney Calculi / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000628:therapy; D000077287:Levetiracetam; D008297:Male; D000078330:Oxcarbazepine; D010889:Piracetam / Q000031:analogs & derivatives / Q000627:therapeutic use; D012008:Recurrence; D014463:Ultrasonography; D014514:Ureteral Calculi / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000628:therapy; D000078305:Zonisamide
D000927:Anticonvulsants; D007555:Isoxazoles; D002220:Carbamazepine; D000077287:Levetiracetam; D000078305:Zonisamide; D019355:Calcium Citrate; D000078330:Oxcarbazepine; D010889:Piracetam